Pharma & Healthcare
Global Short-acting GLP-1 Therapy Market Research Report 2025
- Dec 02, 25
- ID: 612594
- Pages: 77
- Figures: 73
- Views: 8
Report Scope
This report aims to provide a comprehensive presentation of the global market for Short-acting GLP-1 Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Short-acting GLP-1 Therapy.
The Short-acting GLP-1 Therapy market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Short-acting GLP-1 Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, by Feature and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Short-acting GLP-1 Therapy manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, by Feature and by regions.
By Company
Sanofi
AstraZeneca
Amneal Pharmaceuticals
Segment by Type
Injection
Oral
Segment by Feature
GLP-1 Receptor Agonists
Co-agonists
Segment by Channel
Online Sales
Offline Sales
Segment by Application
Type 2 Diabetes
Obesity/Weight Management
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Short-acting GLP-1 Therapy manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Short-acting GLP-1 Therapy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
This report aims to provide a comprehensive presentation of the global market for Short-acting GLP-1 Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Short-acting GLP-1 Therapy.
The Short-acting GLP-1 Therapy market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Short-acting GLP-1 Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, by Feature and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Short-acting GLP-1 Therapy manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, by Feature and by regions.
By Company
Sanofi
AstraZeneca
Amneal Pharmaceuticals
Segment by Type
Injection
Oral
Segment by Feature
GLP-1 Receptor Agonists
Co-agonists
Segment by Channel
Online Sales
Offline Sales
Segment by Application
Type 2 Diabetes
Obesity/Weight Management
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Short-acting GLP-1 Therapy manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Short-acting GLP-1 Therapy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
1 Short-acting GLP-1 Therapy Market Overview
1.1 Product Definition
1.2 Short-acting GLP-1 Therapy by Type
1.2.1 Global Short-acting GLP-1 Therapy Market Value Comparison by Type (2024 VS 2031)
1.2.2 Injection
1.2.3 Oral
1.3 Short-acting GLP-1 Therapy by Feature
1.3.1 Global Short-acting GLP-1 Therapy Market Value Comparison by Feature: 2024 VS 2031
1.3.2 GLP-1 Receptor Agonists
1.3.3 Co-agonists
1.4 Short-acting GLP-1 Therapy by Channel
1.4.1 Global Short-acting GLP-1 Therapy Market Value Comparison by Channel: 2024 VS 2031
1.4.2 Online Sales
1.4.3 Offline Sales
1.5 Short-acting GLP-1 Therapy by Application
1.5.1 Global Short-acting GLP-1 Therapy Market Value by Application (2024 VS 2031)
1.5.2 Type 2 Diabetes
1.5.3 Obesity/Weight Management
1.5.4 Other
1.6 Global Short-acting GLP-1 Therapy Market Size Estimates and Forecasts
1.6.1 Global Short-acting GLP-1 Therapy Revenue 2020-2031
1.6.2 Global Short-acting GLP-1 Therapy Sales 2020-2031
1.6.3 Global Short-acting GLP-1 Therapy Market Average Price (2020-2031)
1.7 Assumptions and Limitations
2 Short-acting GLP-1 Therapy Market Competition by Manufacturers
2.1 Global Short-acting GLP-1 Therapy Sales Market Share by Manufacturers (2020-2025)
2.2 Global Short-acting GLP-1 Therapy Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Short-acting GLP-1 Therapy Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Short-acting GLP-1 Therapy, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Short-acting GLP-1 Therapy, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Short-acting GLP-1 Therapy, Product Type & Application
2.7 Global Key Manufacturers of Short-acting GLP-1 Therapy, Date of Enter into This Industry
2.8 Global Short-acting GLP-1 Therapy Market Competitive Situation and Trends
2.8.1 Global Short-acting GLP-1 Therapy Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Short-acting GLP-1 Therapy Players Market Share by Revenue
2.8.3 Global Short-acting GLP-1 Therapy Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Short-acting GLP-1 Therapy Market Scenario by Region
3.1 Global Short-acting GLP-1 Therapy Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Short-acting GLP-1 Therapy Sales by Region: 2020-2031
3.2.1 Global Short-acting GLP-1 Therapy Sales by Region: 2020-2025
3.2.2 Global Short-acting GLP-1 Therapy Sales by Region: 2026-2031
3.3 Global Short-acting GLP-1 Therapy Revenue by Region: 2020-2031
3.3.1 Global Short-acting GLP-1 Therapy Revenue by Region: 2020-2025
3.3.2 Global Short-acting GLP-1 Therapy Revenue by Region: 2026-2031
3.4 North America Short-acting GLP-1 Therapy Market Facts & Figures by Country
3.4.1 North America Short-acting GLP-1 Therapy Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Short-acting GLP-1 Therapy Sales by Country (2020-2031)
3.4.3 North America Short-acting GLP-1 Therapy Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Short-acting GLP-1 Therapy Market Facts & Figures by Country
3.5.1 Europe Short-acting GLP-1 Therapy Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Short-acting GLP-1 Therapy Sales by Country (2020-2031)
3.5.3 Europe Short-acting GLP-1 Therapy Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Short-acting GLP-1 Therapy Market Facts & Figures by Region
3.6.1 Asia Pacific Short-acting GLP-1 Therapy Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Short-acting GLP-1 Therapy Sales by Region (2020-2031)
3.6.3 Asia Pacific Short-acting GLP-1 Therapy Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Short-acting GLP-1 Therapy Market Facts & Figures by Country
3.7.1 Latin America Short-acting GLP-1 Therapy Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Short-acting GLP-1 Therapy Sales by Country (2020-2031)
3.7.3 Latin America Short-acting GLP-1 Therapy Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Short-acting GLP-1 Therapy Market Facts & Figures by Country
3.8.1 Middle East and Africa Short-acting GLP-1 Therapy Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Short-acting GLP-1 Therapy Sales by Country (2020-2031)
3.8.3 Middle East and Africa Short-acting GLP-1 Therapy Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Short-acting GLP-1 Therapy Sales by Type (2020-2031)
4.1.1 Global Short-acting GLP-1 Therapy Sales by Type (2020-2025)
4.1.2 Global Short-acting GLP-1 Therapy Sales by Type (2026-2031)
4.1.3 Global Short-acting GLP-1 Therapy Sales Market Share by Type (2020-2031)
4.2 Global Short-acting GLP-1 Therapy Revenue by Type (2020-2031)
4.2.1 Global Short-acting GLP-1 Therapy Revenue by Type (2020-2025)
4.2.2 Global Short-acting GLP-1 Therapy Revenue by Type (2026-2031)
4.2.3 Global Short-acting GLP-1 Therapy Revenue Market Share by Type (2020-2031)
4.3 Global Short-acting GLP-1 Therapy Price by Type (2020-2031)
5 Segment by Application
5.1 Global Short-acting GLP-1 Therapy Sales by Application (2020-2031)
5.1.1 Global Short-acting GLP-1 Therapy Sales by Application (2020-2025)
5.1.2 Global Short-acting GLP-1 Therapy Sales by Application (2026-2031)
5.1.3 Global Short-acting GLP-1 Therapy Sales Market Share by Application (2020-2031)
5.2 Global Short-acting GLP-1 Therapy Revenue by Application (2020-2031)
5.2.1 Global Short-acting GLP-1 Therapy Revenue by Application (2020-2025)
5.2.2 Global Short-acting GLP-1 Therapy Revenue by Application (2026-2031)
5.2.3 Global Short-acting GLP-1 Therapy Revenue Market Share by Application (2020-2031)
5.3 Global Short-acting GLP-1 Therapy Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Sanofi
6.1.1 Sanofi Company Information
6.1.2 Sanofi Description and Business Overview
6.1.3 Sanofi Short-acting GLP-1 Therapy Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Sanofi Short-acting GLP-1 Therapy Product Portfolio
6.1.5 Sanofi Recent Developments/Updates
6.2 AstraZeneca
6.2.1 AstraZeneca Company Information
6.2.2 AstraZeneca Description and Business Overview
6.2.3 AstraZeneca Short-acting GLP-1 Therapy Sales, Revenue and Gross Margin (2020-2025)
6.2.4 AstraZeneca Short-acting GLP-1 Therapy Product Portfolio
6.2.5 AstraZeneca Recent Developments/Updates
6.3 Amneal Pharmaceuticals
6.3.1 Amneal Pharmaceuticals Company Information
6.3.2 Amneal Pharmaceuticals Description and Business Overview
6.3.3 Amneal Pharmaceuticals Short-acting GLP-1 Therapy Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Amneal Pharmaceuticals Short-acting GLP-1 Therapy Product Portfolio
6.3.5 Amneal Pharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Short-acting GLP-1 Therapy Industry Chain Analysis
7.2 Short-acting GLP-1 Therapy Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Short-acting GLP-1 Therapy Production Mode & Process Analysis
7.4 Short-acting GLP-1 Therapy Sales and Marketing
7.4.1 Short-acting GLP-1 Therapy Sales Channels
7.4.2 Short-acting GLP-1 Therapy Distributors
7.5 Short-acting GLP-1 Therapy Customer Analysis
8 Short-acting GLP-1 Therapy Market Dynamics
8.1 Short-acting GLP-1 Therapy Industry Trends
8.2 Short-acting GLP-1 Therapy Market Drivers
8.3 Short-acting GLP-1 Therapy Market Challenges
8.4 Short-acting GLP-1 Therapy Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
1.1 Product Definition
1.2 Short-acting GLP-1 Therapy by Type
1.2.1 Global Short-acting GLP-1 Therapy Market Value Comparison by Type (2024 VS 2031)
1.2.2 Injection
1.2.3 Oral
1.3 Short-acting GLP-1 Therapy by Feature
1.3.1 Global Short-acting GLP-1 Therapy Market Value Comparison by Feature: 2024 VS 2031
1.3.2 GLP-1 Receptor Agonists
1.3.3 Co-agonists
1.4 Short-acting GLP-1 Therapy by Channel
1.4.1 Global Short-acting GLP-1 Therapy Market Value Comparison by Channel: 2024 VS 2031
1.4.2 Online Sales
1.4.3 Offline Sales
1.5 Short-acting GLP-1 Therapy by Application
1.5.1 Global Short-acting GLP-1 Therapy Market Value by Application (2024 VS 2031)
1.5.2 Type 2 Diabetes
1.5.3 Obesity/Weight Management
1.5.4 Other
1.6 Global Short-acting GLP-1 Therapy Market Size Estimates and Forecasts
1.6.1 Global Short-acting GLP-1 Therapy Revenue 2020-2031
1.6.2 Global Short-acting GLP-1 Therapy Sales 2020-2031
1.6.3 Global Short-acting GLP-1 Therapy Market Average Price (2020-2031)
1.7 Assumptions and Limitations
2 Short-acting GLP-1 Therapy Market Competition by Manufacturers
2.1 Global Short-acting GLP-1 Therapy Sales Market Share by Manufacturers (2020-2025)
2.2 Global Short-acting GLP-1 Therapy Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Short-acting GLP-1 Therapy Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Short-acting GLP-1 Therapy, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Short-acting GLP-1 Therapy, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Short-acting GLP-1 Therapy, Product Type & Application
2.7 Global Key Manufacturers of Short-acting GLP-1 Therapy, Date of Enter into This Industry
2.8 Global Short-acting GLP-1 Therapy Market Competitive Situation and Trends
2.8.1 Global Short-acting GLP-1 Therapy Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Short-acting GLP-1 Therapy Players Market Share by Revenue
2.8.3 Global Short-acting GLP-1 Therapy Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Short-acting GLP-1 Therapy Market Scenario by Region
3.1 Global Short-acting GLP-1 Therapy Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Short-acting GLP-1 Therapy Sales by Region: 2020-2031
3.2.1 Global Short-acting GLP-1 Therapy Sales by Region: 2020-2025
3.2.2 Global Short-acting GLP-1 Therapy Sales by Region: 2026-2031
3.3 Global Short-acting GLP-1 Therapy Revenue by Region: 2020-2031
3.3.1 Global Short-acting GLP-1 Therapy Revenue by Region: 2020-2025
3.3.2 Global Short-acting GLP-1 Therapy Revenue by Region: 2026-2031
3.4 North America Short-acting GLP-1 Therapy Market Facts & Figures by Country
3.4.1 North America Short-acting GLP-1 Therapy Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Short-acting GLP-1 Therapy Sales by Country (2020-2031)
3.4.3 North America Short-acting GLP-1 Therapy Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Short-acting GLP-1 Therapy Market Facts & Figures by Country
3.5.1 Europe Short-acting GLP-1 Therapy Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Short-acting GLP-1 Therapy Sales by Country (2020-2031)
3.5.3 Europe Short-acting GLP-1 Therapy Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Short-acting GLP-1 Therapy Market Facts & Figures by Region
3.6.1 Asia Pacific Short-acting GLP-1 Therapy Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Short-acting GLP-1 Therapy Sales by Region (2020-2031)
3.6.3 Asia Pacific Short-acting GLP-1 Therapy Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Short-acting GLP-1 Therapy Market Facts & Figures by Country
3.7.1 Latin America Short-acting GLP-1 Therapy Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Short-acting GLP-1 Therapy Sales by Country (2020-2031)
3.7.3 Latin America Short-acting GLP-1 Therapy Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Short-acting GLP-1 Therapy Market Facts & Figures by Country
3.8.1 Middle East and Africa Short-acting GLP-1 Therapy Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Short-acting GLP-1 Therapy Sales by Country (2020-2031)
3.8.3 Middle East and Africa Short-acting GLP-1 Therapy Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Short-acting GLP-1 Therapy Sales by Type (2020-2031)
4.1.1 Global Short-acting GLP-1 Therapy Sales by Type (2020-2025)
4.1.2 Global Short-acting GLP-1 Therapy Sales by Type (2026-2031)
4.1.3 Global Short-acting GLP-1 Therapy Sales Market Share by Type (2020-2031)
4.2 Global Short-acting GLP-1 Therapy Revenue by Type (2020-2031)
4.2.1 Global Short-acting GLP-1 Therapy Revenue by Type (2020-2025)
4.2.2 Global Short-acting GLP-1 Therapy Revenue by Type (2026-2031)
4.2.3 Global Short-acting GLP-1 Therapy Revenue Market Share by Type (2020-2031)
4.3 Global Short-acting GLP-1 Therapy Price by Type (2020-2031)
5 Segment by Application
5.1 Global Short-acting GLP-1 Therapy Sales by Application (2020-2031)
5.1.1 Global Short-acting GLP-1 Therapy Sales by Application (2020-2025)
5.1.2 Global Short-acting GLP-1 Therapy Sales by Application (2026-2031)
5.1.3 Global Short-acting GLP-1 Therapy Sales Market Share by Application (2020-2031)
5.2 Global Short-acting GLP-1 Therapy Revenue by Application (2020-2031)
5.2.1 Global Short-acting GLP-1 Therapy Revenue by Application (2020-2025)
5.2.2 Global Short-acting GLP-1 Therapy Revenue by Application (2026-2031)
5.2.3 Global Short-acting GLP-1 Therapy Revenue Market Share by Application (2020-2031)
5.3 Global Short-acting GLP-1 Therapy Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Sanofi
6.1.1 Sanofi Company Information
6.1.2 Sanofi Description and Business Overview
6.1.3 Sanofi Short-acting GLP-1 Therapy Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Sanofi Short-acting GLP-1 Therapy Product Portfolio
6.1.5 Sanofi Recent Developments/Updates
6.2 AstraZeneca
6.2.1 AstraZeneca Company Information
6.2.2 AstraZeneca Description and Business Overview
6.2.3 AstraZeneca Short-acting GLP-1 Therapy Sales, Revenue and Gross Margin (2020-2025)
6.2.4 AstraZeneca Short-acting GLP-1 Therapy Product Portfolio
6.2.5 AstraZeneca Recent Developments/Updates
6.3 Amneal Pharmaceuticals
6.3.1 Amneal Pharmaceuticals Company Information
6.3.2 Amneal Pharmaceuticals Description and Business Overview
6.3.3 Amneal Pharmaceuticals Short-acting GLP-1 Therapy Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Amneal Pharmaceuticals Short-acting GLP-1 Therapy Product Portfolio
6.3.5 Amneal Pharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Short-acting GLP-1 Therapy Industry Chain Analysis
7.2 Short-acting GLP-1 Therapy Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Short-acting GLP-1 Therapy Production Mode & Process Analysis
7.4 Short-acting GLP-1 Therapy Sales and Marketing
7.4.1 Short-acting GLP-1 Therapy Sales Channels
7.4.2 Short-acting GLP-1 Therapy Distributors
7.5 Short-acting GLP-1 Therapy Customer Analysis
8 Short-acting GLP-1 Therapy Market Dynamics
8.1 Short-acting GLP-1 Therapy Industry Trends
8.2 Short-acting GLP-1 Therapy Market Drivers
8.3 Short-acting GLP-1 Therapy Market Challenges
8.4 Short-acting GLP-1 Therapy Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Short-acting GLP-1 Therapy Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Short-acting GLP-1 Therapy Market Value by Feature, (US$ Million) & (2024 VS 2031)
Table 3. Global Short-acting GLP-1 Therapy Market Value by Channel, (US$ Million) & (2024 VS 2031)
Table 4. Global Short-acting GLP-1 Therapy Market Value by Application (2024 VS 2031) & (US$ Million)
Table 5. Global Short-acting GLP-1 Therapy Market Competitive Situation by Manufacturers in 2024
Table 6. Global Short-acting GLP-1 Therapy Sales (K Units) of Key Manufacturers (2020-2025)
Table 7. Global Short-acting GLP-1 Therapy Sales Market Share by Manufacturers (2020-2025)
Table 8. Global Short-acting GLP-1 Therapy Revenue (US$ Million) by Manufacturers (2020-2025)
Table 9. Global Short-acting GLP-1 Therapy Revenue Share by Manufacturers (2020-2025)
Table 10. Global Market Short-acting GLP-1 Therapy Average Price (US$/Unit) of Key Manufacturers (2020-2025)
Table 11. Global Key Players of Short-acting GLP-1 Therapy, Industry Ranking, 2022 VS 2023 VS 2024
Table 12. Global Key Manufacturers of Short-acting GLP-1 Therapy, Manufacturing Sites & Headquarters
Table 13. Global Key Manufacturers of Short-acting GLP-1 Therapy, Product Type & Application
Table 14. Global Key Manufacturers of Short-acting GLP-1 Therapy, Date of Enter into This Industry
Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 16. Global Short-acting GLP-1 Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Short-acting GLP-1 Therapy as of 2024)
Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 18. Global Short-acting GLP-1 Therapy Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 19. Global Short-acting GLP-1 Therapy Sales by Region (2020-2025) & (K Units)
Table 20. Global Short-acting GLP-1 Therapy Sales Market Share by Region (2020-2025)
Table 21. Global Short-acting GLP-1 Therapy Sales by Region (2026-2031) & (K Units)
Table 22. Global Short-acting GLP-1 Therapy Sales Market Share by Region (2026-2031)
Table 23. Global Short-acting GLP-1 Therapy Revenue by Region (2020-2025) & (US$ Million)
Table 24. Global Short-acting GLP-1 Therapy Revenue Market Share by Region (2020-2025)
Table 25. Global Short-acting GLP-1 Therapy Revenue by Region (2026-2031) & (US$ Million)
Table 26. Global Short-acting GLP-1 Therapy Revenue Market Share by Region (2026-2031)
Table 27. North America Short-acting GLP-1 Therapy Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. North America Short-acting GLP-1 Therapy Sales by Country (2020-2025) & (K Units)
Table 29. North America Short-acting GLP-1 Therapy Sales by Country (2026-2031) & (K Units)
Table 30. North America Short-acting GLP-1 Therapy Revenue by Country (2020-2025) & (US$ Million)
Table 31. North America Short-acting GLP-1 Therapy Revenue by Country (2026-2031) & (US$ Million)
Table 32. Europe Short-acting GLP-1 Therapy Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 33. Europe Short-acting GLP-1 Therapy Sales by Country (2020-2025) & (K Units)
Table 34. Europe Short-acting GLP-1 Therapy Sales by Country (2026-2031) & (K Units)
Table 35. Europe Short-acting GLP-1 Therapy Revenue by Country (2020-2025) & (US$ Million)
Table 36. Europe Short-acting GLP-1 Therapy Revenue by Country (2026-2031) & (US$ Million)
Table 37. Asia Pacific Short-acting GLP-1 Therapy Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 38. Asia Pacific Short-acting GLP-1 Therapy Sales by Region (2020-2025) & (K Units)
Table 39. Asia Pacific Short-acting GLP-1 Therapy Sales by Region (2026-2031) & (K Units)
Table 40. Asia Pacific Short-acting GLP-1 Therapy Revenue by Region (2020-2025) & (US$ Million)
Table 41. Asia Pacific Short-acting GLP-1 Therapy Revenue by Region (2026-2031) & (US$ Million)
Table 42. Latin America Short-acting GLP-1 Therapy Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Latin America Short-acting GLP-1 Therapy Sales by Country (2020-2025) & (K Units)
Table 44. Latin America Short-acting GLP-1 Therapy Sales by Country (2026-2031) & (K Units)
Table 45. Latin America Short-acting GLP-1 Therapy Revenue by Country (2020-2025) & (US$ Million)
Table 46. Latin America Short-acting GLP-1 Therapy Revenue by Country (2026-2031) & (US$ Million)
Table 47. Middle East and Africa Short-acting GLP-1 Therapy Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 48. Middle East and Africa Short-acting GLP-1 Therapy Sales by Country (2020-2025) & (K Units)
Table 49. Middle East and Africa Short-acting GLP-1 Therapy Sales by Country (2026-2031) & (K Units)
Table 50. Middle East and Africa Short-acting GLP-1 Therapy Revenue by Country (2020-2025) & (US$ Million)
Table 51. Middle East and Africa Short-acting GLP-1 Therapy Revenue by Country (2026-2031) & (US$ Million)
Table 52. Global Short-acting GLP-1 Therapy Sales (K Units) by Type (2020-2025)
Table 53. Global Short-acting GLP-1 Therapy Sales (K Units) by Type (2026-2031)
Table 54. Global Short-acting GLP-1 Therapy Sales Market Share by Type (2020-2025)
Table 55. Global Short-acting GLP-1 Therapy Sales Market Share by Type (2026-2031)
Table 56. Global Short-acting GLP-1 Therapy Revenue (US$ Million) by Type (2020-2025)
Table 57. Global Short-acting GLP-1 Therapy Revenue (US$ Million) by Type (2026-2031)
Table 58. Global Short-acting GLP-1 Therapy Revenue Market Share by Type (2020-2025)
Table 59. Global Short-acting GLP-1 Therapy Revenue Market Share by Type (2026-2031)
Table 60. Global Short-acting GLP-1 Therapy Price (US$/Unit) by Type (2020-2025)
Table 61. Global Short-acting GLP-1 Therapy Price (US$/Unit) by Type (2026-2031)
Table 62. Global Short-acting GLP-1 Therapy Sales (K Units) by Application (2020-2025)
Table 63. Global Short-acting GLP-1 Therapy Sales (K Units) by Application (2026-2031)
Table 64. Global Short-acting GLP-1 Therapy Sales Market Share by Application (2020-2025)
Table 65. Global Short-acting GLP-1 Therapy Sales Market Share by Application (2026-2031)
Table 66. Global Short-acting GLP-1 Therapy Revenue (US$ Million) by Application (2020-2025)
Table 67. Global Short-acting GLP-1 Therapy Revenue (US$ Million) by Application (2026-2031)
Table 68. Global Short-acting GLP-1 Therapy Revenue Market Share by Application (2020-2025)
Table 69. Global Short-acting GLP-1 Therapy Revenue Market Share by Application (2026-2031)
Table 70. Global Short-acting GLP-1 Therapy Price (US$/Unit) by Application (2020-2025)
Table 71. Global Short-acting GLP-1 Therapy Price (US$/Unit) by Application (2026-2031)
Table 72. Sanofi Company Information
Table 73. Sanofi Description and Business Overview
Table 74. Sanofi Short-acting GLP-1 Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 75. Sanofi Short-acting GLP-1 Therapy Product
Table 76. Sanofi Recent Developments/Updates
Table 77. AstraZeneca Company Information
Table 78. AstraZeneca Description and Business Overview
Table 79. AstraZeneca Short-acting GLP-1 Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 80. AstraZeneca Short-acting GLP-1 Therapy Product
Table 81. AstraZeneca Recent Developments/Updates
Table 82. Amneal Pharmaceuticals Company Information
Table 83. Amneal Pharmaceuticals Description and Business Overview
Table 84. Amneal Pharmaceuticals Short-acting GLP-1 Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 85. Amneal Pharmaceuticals Short-acting GLP-1 Therapy Product
Table 86. Amneal Pharmaceuticals Recent Developments/Updates
Table 87. Key Raw Materials Lists
Table 88. Raw Materials Key Suppliers Lists
Table 89. Short-acting GLP-1 Therapy Distributors List
Table 90. Short-acting GLP-1 Therapy Customers List
Table 91. Short-acting GLP-1 Therapy Market Trends
Table 92. Short-acting GLP-1 Therapy Market Drivers
Table 93. Short-acting GLP-1 Therapy Market Challenges
Table 94. Short-acting GLP-1 Therapy Market Restraints
Table 95. Research Programs/Design for This Report
Table 96. Key Data Information from Secondary Sources
Table 97. Key Data Information from Primary Sources
Table 98. Authors List of This Report
List of Figures
Figure 1. Product Picture of Short-acting GLP-1 Therapy
Figure 2. Global Short-acting GLP-1 Therapy Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Short-acting GLP-1 Therapy Market Share by Type: 2024 & 2031
Figure 4. Injection Product Picture
Figure 5. Oral Product Picture
Figure 6. Global Short-acting GLP-1 Therapy Market Value by Feature, (US$ Million) & (2020-2031)
Figure 7. Global Short-acting GLP-1 Therapy Market Share by Feature: 2024 VS 2031
Figure 8. GLP-1 Receptor Agonists Product Picture
Figure 9. Co-agonists Product Picture
Figure 10. Global Short-acting GLP-1 Therapy Market Value by Channel, (US$ Million) & (2020-2031)
Figure 11. Global Short-acting GLP-1 Therapy Market Share by Channel: 2024 VS 2031
Figure 12. Online Sales Product Picture
Figure 13. Offline Sales Product Picture
Figure 14. Global Short-acting GLP-1 Therapy Market Value by Application (2020-2031) & (US$ Million)
Figure 15. Global Short-acting GLP-1 Therapy Market Share by Application: 2024 & 2031
Figure 16. Type 2 Diabetes
Figure 17. Obesity/Weight Management
Figure 18. Other
Figure 19. Global Short-acting GLP-1 Therapy Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 20. Global Short-acting GLP-1 Therapy Market Size (2020-2031) & (US$ Million)
Figure 21. Global Short-acting GLP-1 Therapy Sales (2020-2031) & (K Units)
Figure 22. Global Short-acting GLP-1 Therapy Average Price (US$/Unit) & (2020-2031)
Figure 23. Short-acting GLP-1 Therapy Report Years Considered
Figure 24. Short-acting GLP-1 Therapy Sales Share by Manufacturers in 2024
Figure 25. Global Short-acting GLP-1 Therapy Revenue Share by Manufacturers in 2024
Figure 26. Global 5 and 10 Largest Short-acting GLP-1 Therapy Players: Market Share by Revenue in Short-acting GLP-1 Therapy in 2024
Figure 27. Short-acting GLP-1 Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 28. Global Short-acting GLP-1 Therapy Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 29. North America Short-acting GLP-1 Therapy Sales Market Share by Country (2020-2031)
Figure 30. North America Short-acting GLP-1 Therapy Revenue Market Share by Country (2020-2031)
Figure 31. United States Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. Canada Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. Europe Short-acting GLP-1 Therapy Sales Market Share by Country (2020-2031)
Figure 34. Europe Short-acting GLP-1 Therapy Revenue Market Share by Country (2020-2031)
Figure 35. Germany Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. France Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. U.K. Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. Italy Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. Russia Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. Asia Pacific Short-acting GLP-1 Therapy Sales Market Share by Region (2020-2031)
Figure 41. Asia Pacific Short-acting GLP-1 Therapy Revenue Market Share by Region (2020-2031)
Figure 42. China Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. Japan Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. South Korea Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. India Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. Australia Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. China Taiwan Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. Southeast Asia Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 49. Latin America Short-acting GLP-1 Therapy Sales Market Share by Country (2020-2031)
Figure 50. Latin America Short-acting GLP-1 Therapy Revenue Market Share by Country (2020-2031)
Figure 51. Mexico Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. Brazil Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 53. Argentina Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 54. Colombia Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 55. Middle East and Africa Short-acting GLP-1 Therapy Sales Market Share by Country (2020-2031)
Figure 56. Middle East and Africa Short-acting GLP-1 Therapy Revenue Market Share by Country (2020-2031)
Figure 57. Turkey Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 58. Saudi Arabia Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 59. UAE Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 60. Global Sales Market Share of Short-acting GLP-1 Therapy by Type (2020-2031)
Figure 61. Global Revenue Market Share of Short-acting GLP-1 Therapy by Type (2020-2031)
Figure 62. Global Short-acting GLP-1 Therapy Price (US$/Unit) by Type (2020-2031)
Figure 63. Global Sales Market Share of Short-acting GLP-1 Therapy by Application (2020-2031)
Figure 64. Global Revenue Market Share of Short-acting GLP-1 Therapy by Application (2020-2031)
Figure 65. Global Short-acting GLP-1 Therapy Price (US$/Unit) by Application (2020-2031)
Figure 66. Short-acting GLP-1 Therapy Value Chain
Figure 67. Channels of Distribution (Direct Vs Distribution)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
Table 1. Global Short-acting GLP-1 Therapy Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Short-acting GLP-1 Therapy Market Value by Feature, (US$ Million) & (2024 VS 2031)
Table 3. Global Short-acting GLP-1 Therapy Market Value by Channel, (US$ Million) & (2024 VS 2031)
Table 4. Global Short-acting GLP-1 Therapy Market Value by Application (2024 VS 2031) & (US$ Million)
Table 5. Global Short-acting GLP-1 Therapy Market Competitive Situation by Manufacturers in 2024
Table 6. Global Short-acting GLP-1 Therapy Sales (K Units) of Key Manufacturers (2020-2025)
Table 7. Global Short-acting GLP-1 Therapy Sales Market Share by Manufacturers (2020-2025)
Table 8. Global Short-acting GLP-1 Therapy Revenue (US$ Million) by Manufacturers (2020-2025)
Table 9. Global Short-acting GLP-1 Therapy Revenue Share by Manufacturers (2020-2025)
Table 10. Global Market Short-acting GLP-1 Therapy Average Price (US$/Unit) of Key Manufacturers (2020-2025)
Table 11. Global Key Players of Short-acting GLP-1 Therapy, Industry Ranking, 2022 VS 2023 VS 2024
Table 12. Global Key Manufacturers of Short-acting GLP-1 Therapy, Manufacturing Sites & Headquarters
Table 13. Global Key Manufacturers of Short-acting GLP-1 Therapy, Product Type & Application
Table 14. Global Key Manufacturers of Short-acting GLP-1 Therapy, Date of Enter into This Industry
Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 16. Global Short-acting GLP-1 Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Short-acting GLP-1 Therapy as of 2024)
Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 18. Global Short-acting GLP-1 Therapy Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 19. Global Short-acting GLP-1 Therapy Sales by Region (2020-2025) & (K Units)
Table 20. Global Short-acting GLP-1 Therapy Sales Market Share by Region (2020-2025)
Table 21. Global Short-acting GLP-1 Therapy Sales by Region (2026-2031) & (K Units)
Table 22. Global Short-acting GLP-1 Therapy Sales Market Share by Region (2026-2031)
Table 23. Global Short-acting GLP-1 Therapy Revenue by Region (2020-2025) & (US$ Million)
Table 24. Global Short-acting GLP-1 Therapy Revenue Market Share by Region (2020-2025)
Table 25. Global Short-acting GLP-1 Therapy Revenue by Region (2026-2031) & (US$ Million)
Table 26. Global Short-acting GLP-1 Therapy Revenue Market Share by Region (2026-2031)
Table 27. North America Short-acting GLP-1 Therapy Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. North America Short-acting GLP-1 Therapy Sales by Country (2020-2025) & (K Units)
Table 29. North America Short-acting GLP-1 Therapy Sales by Country (2026-2031) & (K Units)
Table 30. North America Short-acting GLP-1 Therapy Revenue by Country (2020-2025) & (US$ Million)
Table 31. North America Short-acting GLP-1 Therapy Revenue by Country (2026-2031) & (US$ Million)
Table 32. Europe Short-acting GLP-1 Therapy Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 33. Europe Short-acting GLP-1 Therapy Sales by Country (2020-2025) & (K Units)
Table 34. Europe Short-acting GLP-1 Therapy Sales by Country (2026-2031) & (K Units)
Table 35. Europe Short-acting GLP-1 Therapy Revenue by Country (2020-2025) & (US$ Million)
Table 36. Europe Short-acting GLP-1 Therapy Revenue by Country (2026-2031) & (US$ Million)
Table 37. Asia Pacific Short-acting GLP-1 Therapy Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 38. Asia Pacific Short-acting GLP-1 Therapy Sales by Region (2020-2025) & (K Units)
Table 39. Asia Pacific Short-acting GLP-1 Therapy Sales by Region (2026-2031) & (K Units)
Table 40. Asia Pacific Short-acting GLP-1 Therapy Revenue by Region (2020-2025) & (US$ Million)
Table 41. Asia Pacific Short-acting GLP-1 Therapy Revenue by Region (2026-2031) & (US$ Million)
Table 42. Latin America Short-acting GLP-1 Therapy Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Latin America Short-acting GLP-1 Therapy Sales by Country (2020-2025) & (K Units)
Table 44. Latin America Short-acting GLP-1 Therapy Sales by Country (2026-2031) & (K Units)
Table 45. Latin America Short-acting GLP-1 Therapy Revenue by Country (2020-2025) & (US$ Million)
Table 46. Latin America Short-acting GLP-1 Therapy Revenue by Country (2026-2031) & (US$ Million)
Table 47. Middle East and Africa Short-acting GLP-1 Therapy Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 48. Middle East and Africa Short-acting GLP-1 Therapy Sales by Country (2020-2025) & (K Units)
Table 49. Middle East and Africa Short-acting GLP-1 Therapy Sales by Country (2026-2031) & (K Units)
Table 50. Middle East and Africa Short-acting GLP-1 Therapy Revenue by Country (2020-2025) & (US$ Million)
Table 51. Middle East and Africa Short-acting GLP-1 Therapy Revenue by Country (2026-2031) & (US$ Million)
Table 52. Global Short-acting GLP-1 Therapy Sales (K Units) by Type (2020-2025)
Table 53. Global Short-acting GLP-1 Therapy Sales (K Units) by Type (2026-2031)
Table 54. Global Short-acting GLP-1 Therapy Sales Market Share by Type (2020-2025)
Table 55. Global Short-acting GLP-1 Therapy Sales Market Share by Type (2026-2031)
Table 56. Global Short-acting GLP-1 Therapy Revenue (US$ Million) by Type (2020-2025)
Table 57. Global Short-acting GLP-1 Therapy Revenue (US$ Million) by Type (2026-2031)
Table 58. Global Short-acting GLP-1 Therapy Revenue Market Share by Type (2020-2025)
Table 59. Global Short-acting GLP-1 Therapy Revenue Market Share by Type (2026-2031)
Table 60. Global Short-acting GLP-1 Therapy Price (US$/Unit) by Type (2020-2025)
Table 61. Global Short-acting GLP-1 Therapy Price (US$/Unit) by Type (2026-2031)
Table 62. Global Short-acting GLP-1 Therapy Sales (K Units) by Application (2020-2025)
Table 63. Global Short-acting GLP-1 Therapy Sales (K Units) by Application (2026-2031)
Table 64. Global Short-acting GLP-1 Therapy Sales Market Share by Application (2020-2025)
Table 65. Global Short-acting GLP-1 Therapy Sales Market Share by Application (2026-2031)
Table 66. Global Short-acting GLP-1 Therapy Revenue (US$ Million) by Application (2020-2025)
Table 67. Global Short-acting GLP-1 Therapy Revenue (US$ Million) by Application (2026-2031)
Table 68. Global Short-acting GLP-1 Therapy Revenue Market Share by Application (2020-2025)
Table 69. Global Short-acting GLP-1 Therapy Revenue Market Share by Application (2026-2031)
Table 70. Global Short-acting GLP-1 Therapy Price (US$/Unit) by Application (2020-2025)
Table 71. Global Short-acting GLP-1 Therapy Price (US$/Unit) by Application (2026-2031)
Table 72. Sanofi Company Information
Table 73. Sanofi Description and Business Overview
Table 74. Sanofi Short-acting GLP-1 Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 75. Sanofi Short-acting GLP-1 Therapy Product
Table 76. Sanofi Recent Developments/Updates
Table 77. AstraZeneca Company Information
Table 78. AstraZeneca Description and Business Overview
Table 79. AstraZeneca Short-acting GLP-1 Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 80. AstraZeneca Short-acting GLP-1 Therapy Product
Table 81. AstraZeneca Recent Developments/Updates
Table 82. Amneal Pharmaceuticals Company Information
Table 83. Amneal Pharmaceuticals Description and Business Overview
Table 84. Amneal Pharmaceuticals Short-acting GLP-1 Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 85. Amneal Pharmaceuticals Short-acting GLP-1 Therapy Product
Table 86. Amneal Pharmaceuticals Recent Developments/Updates
Table 87. Key Raw Materials Lists
Table 88. Raw Materials Key Suppliers Lists
Table 89. Short-acting GLP-1 Therapy Distributors List
Table 90. Short-acting GLP-1 Therapy Customers List
Table 91. Short-acting GLP-1 Therapy Market Trends
Table 92. Short-acting GLP-1 Therapy Market Drivers
Table 93. Short-acting GLP-1 Therapy Market Challenges
Table 94. Short-acting GLP-1 Therapy Market Restraints
Table 95. Research Programs/Design for This Report
Table 96. Key Data Information from Secondary Sources
Table 97. Key Data Information from Primary Sources
Table 98. Authors List of This Report
List of Figures
Figure 1. Product Picture of Short-acting GLP-1 Therapy
Figure 2. Global Short-acting GLP-1 Therapy Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Short-acting GLP-1 Therapy Market Share by Type: 2024 & 2031
Figure 4. Injection Product Picture
Figure 5. Oral Product Picture
Figure 6. Global Short-acting GLP-1 Therapy Market Value by Feature, (US$ Million) & (2020-2031)
Figure 7. Global Short-acting GLP-1 Therapy Market Share by Feature: 2024 VS 2031
Figure 8. GLP-1 Receptor Agonists Product Picture
Figure 9. Co-agonists Product Picture
Figure 10. Global Short-acting GLP-1 Therapy Market Value by Channel, (US$ Million) & (2020-2031)
Figure 11. Global Short-acting GLP-1 Therapy Market Share by Channel: 2024 VS 2031
Figure 12. Online Sales Product Picture
Figure 13. Offline Sales Product Picture
Figure 14. Global Short-acting GLP-1 Therapy Market Value by Application (2020-2031) & (US$ Million)
Figure 15. Global Short-acting GLP-1 Therapy Market Share by Application: 2024 & 2031
Figure 16. Type 2 Diabetes
Figure 17. Obesity/Weight Management
Figure 18. Other
Figure 19. Global Short-acting GLP-1 Therapy Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 20. Global Short-acting GLP-1 Therapy Market Size (2020-2031) & (US$ Million)
Figure 21. Global Short-acting GLP-1 Therapy Sales (2020-2031) & (K Units)
Figure 22. Global Short-acting GLP-1 Therapy Average Price (US$/Unit) & (2020-2031)
Figure 23. Short-acting GLP-1 Therapy Report Years Considered
Figure 24. Short-acting GLP-1 Therapy Sales Share by Manufacturers in 2024
Figure 25. Global Short-acting GLP-1 Therapy Revenue Share by Manufacturers in 2024
Figure 26. Global 5 and 10 Largest Short-acting GLP-1 Therapy Players: Market Share by Revenue in Short-acting GLP-1 Therapy in 2024
Figure 27. Short-acting GLP-1 Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 28. Global Short-acting GLP-1 Therapy Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 29. North America Short-acting GLP-1 Therapy Sales Market Share by Country (2020-2031)
Figure 30. North America Short-acting GLP-1 Therapy Revenue Market Share by Country (2020-2031)
Figure 31. United States Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. Canada Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. Europe Short-acting GLP-1 Therapy Sales Market Share by Country (2020-2031)
Figure 34. Europe Short-acting GLP-1 Therapy Revenue Market Share by Country (2020-2031)
Figure 35. Germany Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. France Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. U.K. Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. Italy Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. Russia Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. Asia Pacific Short-acting GLP-1 Therapy Sales Market Share by Region (2020-2031)
Figure 41. Asia Pacific Short-acting GLP-1 Therapy Revenue Market Share by Region (2020-2031)
Figure 42. China Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. Japan Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. South Korea Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. India Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. Australia Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. China Taiwan Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. Southeast Asia Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 49. Latin America Short-acting GLP-1 Therapy Sales Market Share by Country (2020-2031)
Figure 50. Latin America Short-acting GLP-1 Therapy Revenue Market Share by Country (2020-2031)
Figure 51. Mexico Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. Brazil Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 53. Argentina Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 54. Colombia Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 55. Middle East and Africa Short-acting GLP-1 Therapy Sales Market Share by Country (2020-2031)
Figure 56. Middle East and Africa Short-acting GLP-1 Therapy Revenue Market Share by Country (2020-2031)
Figure 57. Turkey Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 58. Saudi Arabia Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 59. UAE Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 60. Global Sales Market Share of Short-acting GLP-1 Therapy by Type (2020-2031)
Figure 61. Global Revenue Market Share of Short-acting GLP-1 Therapy by Type (2020-2031)
Figure 62. Global Short-acting GLP-1 Therapy Price (US$/Unit) by Type (2020-2031)
Figure 63. Global Sales Market Share of Short-acting GLP-1 Therapy by Application (2020-2031)
Figure 64. Global Revenue Market Share of Short-acting GLP-1 Therapy by Application (2020-2031)
Figure 65. Global Short-acting GLP-1 Therapy Price (US$/Unit) by Application (2020-2031)
Figure 66. Short-acting GLP-1 Therapy Value Chain
Figure 67. Channels of Distribution (Direct Vs Distribution)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Potassium Bromide Windows Market Research Report 2025
Dec 14, 25
Global Bio-based 1,10-Decanediol Diacrylate Market Research Report 2025
Dec 14, 25
Global Bio-based 1,5-Pentanediol Diacrylate(PDDA) Market Research Report 2025
Dec 14, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232